Description
What is Veopoz (pozelimab-bbfg) for?
Veopoz (pozelimab-bbfg) is a prescription medicine for children older than 1 year and adults, who have CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease[1].
Veopoz is available as a subcutaneous injection (400 mg/2 mL)[1].
How does Veopoz (pozelimab-bbfg) work?
Pozelimab-bbfg is a specially designed human-made antibody that targets a specific protein called C5. By doing so, it stops a process that can harm cells. This process involves breaking C5 into two parts (C5a and C5b) and then creating a structure that can destroy cells (the membrane-attack complex C5b-C9). By blocking this process, pozelimab-bbfg helps protect cells[1].
Where has Veopoz (pozelimab-bbfg) been approved?
Veopoz (pozelimab-bbfg) is currently approved by the FDA in the USA[2].
Reviews
There are no reviews yet.